Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (2)

Trial Status

Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT05952947Phase 1Recruiting

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

NCT05787535Phase 1Unknown

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Showing all 2 trials

Research Network

Activity Timeline